Evidence map›Paper›PMID 36375566›Full record

ArticleDiabetes research and clinical practice2022

Dexamethasone-induced hyperglycaemia in COVID-19: Glycaemic profile in patients without diabetes and factors associated with hyperglycaemia.

Yoon Ji J Rhou, Amanda Hor, Mawson Wang, Yu-Fang Wu, Suja Jose, David R Chipps, N Wah Cheung

Open access · greenAbstract read
In one paragraph

Article in Diabetes research and clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Post-COVID-19 Jaw Osteonecrosis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Implications of Dysnatremia and Endocrine Disturbances in COVID-19 Patients.International journal of molecular sciences · 2024
    Review
  10. Review
  11. [Current Status of Research on COVID-19 Patients With Concomitant Hyperglycemia and the Management Strategies of Hyperglycemia].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Review
  12. Article
  13. Article
  14. Observational
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yoon Ji J RhouDepartment of Diabetes and Endocrinology, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: jina.rhou@sydney.edu.au.
Amanda HorDepartment of Diabetes and Endocrinology, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia; Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Mawson WangDepartment of Diabetes and Endocrinology, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Yu-Fang WuDepartment of Diabetes and Endocrinology, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
Suja JoseDepartment of Diabetes and Endocrinology, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
David R ChippsDepartment of Diabetes and Endocrinology, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
N Wah CheungDepartment of Diabetes and Endocrinology, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Westmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate glycaemic profiles of COVID-19 patients without diabetes receiving dexamethasone and determine factors associated with hyperglycaemia.

methodsAll subjects without pre-existing diabetes receiving dexamethasone 6 mg for COVID-19 in a non-critical care setting were identified. Glucose profiles were obtained from capillary blood glucose (BG). Univariate and multivariate analyses were performed to identify factors associated with dexamethasone-induced hyperglycaemia (BG ≥ 10 mmol/L).

resultsOf 254 subjects, 129 (50.8%) were male with age 51.1 ± 18.2 years and weight 89.7 ± 26.3 kg. Hyperglycaemia post-dexamethasone occurred in 121 (47.6%). Glucose excursions began within three hours (6.8 ± 1.4 mmol/L pre-dexamethasone vs 8.7 ± 2.4 mmol/L at ≤ 3 h, p < 0.001) and peaked at 7-9 h (10.5 ± 2.3 mmol/L, p < 0.001 vs pre-dexamethasone). BGs post-intravenous were higher than post-oral administration for the initial six hours. Hyperglycaemic subjects were older (57.8 ± 17.5 years vs 45.0 ± 16.6 years, p < 0.001), had higher initial glucose (6.3 ± 1.0 vs 5.9 ± 0.9 mmol/L, p = 0.004), higher HbA1c (5.8 ± 0.3% [40 ± 3.5 mmol/mol] vs 5.5 ± 0.4% [37 ± 4.1 mmol/mol], p < 0.001) higher C-reactive protein (CRP) (100 ± 68 vs 83 ± 58 mg/L, p = 0.026), and lower eGFR (79 ± 17 vs 84 ± 16 mL/min/1.73 m

conclusionsHalf of subjects without diabetes experienced hyperglycaemia post-dexamethasone for COVID-19, peak occurring after 7-9 h. Age, HbA1c and CRP were associated with hyperglycaemia.

Indexed as

COVID-19Diabetes MellitusDiabetes Mellitus, Type 2HyperglycemiaAdultAgedBlood GlucoseDexamethasoneFemaleGlucoseHumansMaleMiddle AgedBlood GlucoseDexamethasoneGlucoseCorticosteroid-induced hyperglycaemiaCOVID-19DexamethasoneGlucocorticoid-induced hyperglycaemiaGlucose profileGlycaemic profile

Identifiers

PMID36375566
PMCPMC9651935
OpenAlexW4308930123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.